

Workshops on Friday May 25

12:30-13:00 Registration
13:00-15:00 First workshop
15:00-15:30 Break
15:30-17:30 Second workshop
18:30-21:30 Trainee & early career networking dinner

Each workshop is 2 hrs long; one can attend 2 workshops; maximum 30 persons per workshop; first come-first served.

WS I Hands on training: laparoscopy and endoscopy

Tutors laparoscopy: Harun Fajkovic, Mesut Remzi, Anna Czech

Tutors endoscopy: Mehmet Özsoy, Kilian Gust, David D'Andrea, Julian Vesper

WS II Surgical tips and tricks from the expert

Radical cystectomy	Axel Merseburger (DE)
Partial nephrectomy	Maria Ribal (SP)
Cava thrombectomy	Vitaly Margulis (USA)
Post-chemotherapeutic RPLND for testis cancer	Axel Heidenreich (DE)

WS III Practical guide for management of adverse events of systemic therapies in GU oncology

Immunotherapy	Andrea Necchi (IT)
TKIs	Manuela Schmindinger (AUT)
Chemotherapy	Franz Stoiber (AUT)
Androgen receptor targeting agents and Xofigo	Gero Kramer (AUT)

B2B Kidney and Urothelial Cancers

under the auspices of

Soci t  Internationale d'Urologie (SIU)

Central European Urological Society (CEUS)

Austrian-Polish Friends of Urology (FOU)

Oncology, Laparoscopic/robotic, and Imaging Working Groups of the Austrian Urological Society ( GU)

The Young Urology Working Group of the Austrian Urological Society ( GU)

Comprehensive Cancer Center and department of Urology, Medical University of Vienna

Date: 26.5.2018

8:00-8:30 **Welcome:** P. Chłosta, S. F. Shariat

8:30-10:00 **Bladder Cancer Session**

Chairs: Shahrokh Shariat (AUT)
 Dejan Bratuš, Slovenian Urological Association (SUA)

8:30-9:20 Debate: Do really all T1 need a reTUR?

8:30-8:35 Case presentation by young urologists

8:35-8:50 Definitely! Anna Czech (PL)

8:50-9:05 Only in select cases... Kilian Gust (AUT)

9:05-9:20 Discussion

9:20-9:40 Clinical management of variant histology Jakub Dobruch (PL)

9:40-10:00 Update on muscle-invasive EAU guidelines Maria Ribal (SP)

10:00-10:30 **Coffee break**

10:30-13:30 **Kidney Cancer Session**

Chairs: Piotr Chłosta, Polish Urological Association (PTU)
 Christoph Klingler, Austrian Urological Association ( GU)

10:30-11:20 Debate: Optimal approach to clinical T1b renal mass

10:30-10:35 Case presentation by young urologists

10:35-10:50 Radical nephrectomy Vitaly Margulis (USA)

10:50-11:05 Partial nephrectomy Pilar Laguna (NL)

11:05-11:20 Discussion

11:20-11:40 Cytoreductive Nephrectomy in the modern age Axel Heidenreich (DE)

11:40-12:00 Metastatic RCC: what is the best sequence? Axel Merseburger (DE)

12:00-13:00 **Lunch break**

13:00-14:30 **Immunotherapy breakthroughs in bladder and kidney cancers**

Chairs: Jean de la Rosette, Soci t  Internationale d'Urologie (SIU)
 Wolfgang Loidl (AUT)

PRELIMINARY PROGRAM

- 13:00-13:20 Emerging biomarkers for immune check-point inhibitors Matthias Preusser (AUT)
- 13:20-13:40 TKIs in the age of IO – a pathway to the optimum Manuela Schmidinger (AUT)
- 13:40-14:00 Mechanisms of resistance to IO: insights from the pre-operative setting Andrea Necchi (IT)
- 14:00-14:20 IO in urothelial cancer - the magic bullet? Maria De Santis (UK)
- 14:20-14:50 Coffee break**
- 14:50-16:00 Upper Tract Urothelial Carcinoma Session**
- Chairs: Harun Fajkovic (AUT)
Ivan Minčík, Slovak Urological Society (SUS)
- 14:50-15:00 Debate: Pre-surgical systemic therapy for high grade locally advanced UTUC
- 14:50-14:55 Case presentation by young urologists
- 14:55-15:10 Radical nephroureterectomy Mesut Remzi (AUT)
- 15:10-15:30 Neo-adjuvant chemotherapy Vitaly Margulis (USA)
- 15:30-15:40 Discussion
- 15:40-16:00 Kidney-sparing management: what is the evidence? Jean de la Rosette (NL)
- 16:00-16:30 Prof Dr Christoph Zielinski (AUT)**
Where immune checkpoint inhibitor treatment meets precision medicine
- 16:50-17:00 Closing remarks** P. Chłosta, J. de la Rosette, S. Shariat

OVERVIEW

The Congress will focus on key clinical topics in the management of kidney and bladder malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies, as well as explore emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. The Congress continues to evolve and expand its coverage of some of the fastest moving areas in the management of genitourinary malignancies. To that end, there will be an expanded focus on bladder cancer and renal cell carcinoma, given recent practice-changing developments that continue to alter the therapeutic landscape in these fields of care. Key questions concerning the application of landmark clinical trial data on emerging targeted and immunotherapeutic options, as well as the application of emerging biomarkers for these tumors, will be answered during expanded sessions on these topics.

This year's B2B Kidney and Bladder Cancer meeting is not to be missed! The activity is sure to continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with these malignancies.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with kidney and bladder malignancies. Urologists, fellows, nurses, physician assistants, pharmacists, researchers, radiologists, nuclear medicine physicians, and other healthcare professionals interested in the treatment of kidney and bladder cancers may also participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

- Describe methods to stratify risk and tumor information that can provide the rationale for clinical decision making in the management of kidney and bladder cancers
- Summarize recommendations that shape current strategies to care for patients with kidney and bladder cancers
- Develop multidisciplinary strategies to optimize outcomes by proactive mitigation of known treatment-related side effects in caring for patients with kidney and bladder cancers
- Assess recent practice-changing clinical trial findings concerning novel compounds or strategies to manage kidney and bladder cancers
- Apply emerging clinical concepts to support the management of kidney and bladder cancers in consideration of evolving treatment paradigms in the field

ATTEND THE TRAINEE & EARLY-CAREER NETWORKING DINNER

The 2018 Trainee & Early-Career Networking Dinner on May 25 will provide attendees a unique opportunity to speak with some of the most respected members of the GU cancer care community in an informal setting. Attendees will gain insight into different career paths and professional development opportunities that will help them establish their own place in the GU cancer field.

It will follow a speed-networking format to facilitate a greater number of connections between attendees and expert faculty. Participants will network with multiple mentors to gain key insights into career paths and opportunities for professional growth.

Who Should Attend?

All early-career doctors or trainees should attend the Dinner. The event's new format and emphasis on providing advice to early-career attendees make this Dinner the ideal networking opportunity for young professionals from all parts of the GU cancer care and research community.

The expert faculty is made up of medical oncologists, urologists, and researchers, so attendees will gain exposure to a wide range of specialties and professional interests.

The Dinner is a first-come, first-served event with a limited number of seats available. Plan on arriving early to secure a seat.

What's on the Agenda?

Dr. Shariat will begin the Dinner by introducing the expert faculty and providing an overview of the new speed-networking format. Following this introduction, attendees will speak with the faculty member seated at their table. Every 30 minutes, each faculty member will move to a different table. By the end of the Dinner, each attendee will have spoken with multiple faculty members. During each 30-minute rotation, the faculty table hosts will provide career and networking advice, as well as answer the following discussion prompts:

- In hindsight, what is one thing you wish you had known about networking, your career path, or the GU oncology field in general?
- What is one networking tip unique to your particular specialty?
- What are your suggestions for avoiding burnout?
- What single characteristic do you look for when hiring physicians or researchers?

Networking beyond the Dinner

At the conclusion of the final rotation, the expert faculty will share other networking opportunities that are taking place at the 2018 B2B Bladder and Kidney Cancer Symposium so that Dinner attendees can continue to network and discuss the topics raised at the Dinner. In addition, faculty and attendees will be encouraged to share their names and mail addresses to answer follow-up questions and continue mentorship after the conclusion of the Symposium.